Pfanstiehl, a leading US-based manufacturer of cGMP high purity, low endotoxin injectable grade excipients and biopharmaceutical components for upstream bioprocessing, downstream formulation, and specialty applications, has announced the establishment of its European subsidiary, Pfanstiehl GmbH. The subsidiary will be anchored in Switzerland, but will provide the foundation to support Pfanstiehl’s growing customer base throughout Europe, the Middle East, and Africa.
Pfanstiehl GmbH will offer the same tried and true, platform-enabling protein stabilizers, lyoprotectants, cell culture media components, and solubilizers as Pfanstiehl, Inc. Such technologies include Trehalose, Sucrose, Mannitol, Sorbitol, Maltose, Galactose, Mannose, and Cyclodextrins.
Grafenaustrasse 3, 6302 Zug Switzerland
